4-O-methylhonokiol attenuated memory impairment through modulation of oxidative damage of enzymes involving amyloid-β generation and accumulation in a mouse model of alzheimer's disease

Journal of Alzheimer's Disease

Volumn 27, Issue 1, 2011, Pages 127-141

  Choi, Im Seop ^a   Lee, Young Jung ^a   Choi, Dong Young ^a   Lee, Yong Kyung ^a   Lee, Yeun Hee ^a   Kim, Ki Ho ^b   Kim, Young Heui ^b   Jeon, Young Ho ^c   Kim, Eun Hee ^d   Han, Sang Bae ^a   Jung, Jae Kyung ^a   Yun, Yeo Pyo ^a   Oh, Ki Wan ^a   Hwang, Dae Youn ^e   Hong, Jin Tae ^a  

^a Chungbuk National University   (South Korea)

^b Bioland Ltd   (South Korea)

^c Korea University   (South Korea)

^d Korea Basic Science Institute (KBSI)   (South Korea)

^e Pusan National University   (South Korea)

Author keywords

4 O methylhonokiol; Alzheimer's disease; amyloid ; A PPsw mouse; oxidative stress

Indexed keywords

4 O METHYLHONOKIOL; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE 1; CASPASE 3; CENTRAL NERVOUS SYSTEM AGENTS; GLUTATHIONE; INSULINASE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MEMBRANE METALLOENDOPEPTIDASE; PROTEIN BAX; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; ENZYME INACTIVATION; ENZYME SYNTHESIS; LIPID PEROXIDATION; MEMORY DISORDER; MOUSE; NERVE CELL NECROSIS; NONHUMAN; OXIDATIVE STRESS; PREMEDICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 80155161305     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-110545     Document Type: Article

References (56)

1. Weiner HL, Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, Issazadeh S, Hancock WW, Selkoe DJ (2000) Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol 48, 567-579.
2. Frank B, Gupta S (2000) A review of antioxidants and Alzheimer's disease. Ann Clin Psychiatry 17, 269-286. (Pubitemid 41780250)
3. Rezai-Zadeh K, Arendash GW, Hou H, Fernandez F, Jensen M, Runfeldt M, Shytle RD, Tan J (2008) Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. Brain Res 1214, 177-187.
4. Nishida Y, Ito S, Ohtsuki S, Yamamoto N, Takahashi T, Iwata N, Jishaga K, Yamada H, Sasaguri H, Yokata S, Piao W, Tomimitsu H, Saido TC, Yanagisawa K, Terasaki T, Mizusawa H, Yokota T (2009) Deletion of vitamin E increases amyloid-accumulation by decreasing its mouse model of Alzheimer disease. J Biol Chem 284, 33400-33408.
5. Yatin SM, Aksenova M, AksenovM,Markesbery WR, Aulick T, Butterfield DA (1998) Temporal relations among amyloid beta-peptide-induced free-radical oxidative stress, neuronal toxicity, and neuronal defensive responses. J Mol Neurosci 11, 183-197. (Pubitemid 29232849)
6. Butterfield DA (2002) Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain.Areview, Free Radic Res 36, 1307-1313. (Pubitemid 35469517)
7. Drouet B, Pinçon-Raymond M, Chambaz J, Pillot T (2000) Molecular basis of Alzheimer's disease. Cell Mol Life Sci 57, 705-715. (Pubitemid 30392029)
8. Jang JH, Surh YJ (2002) Beta-Amyloid induces oxidative DNA damage and cell death through activation of c-Jun N terminal kinase. Ann N Y Acad 973, 228-236.
9. Liou KT, Shen YC, Chen CF, Tsao CM, Tsai SK (2003) Honokiol protects rat brain from focal cerebral ischemiareperfusion injury by inhibiting neutrophil infiltration and reactive oxygen species production. Brain Res 992, 159-166.
10. Lin YR, Chen HH, Ko CH, ChanMH(2006) Neuroprotective activity of honokiol and magnolol in cerebellar granule cell damage. Eur J Pharmacol 537, 64-69.
11. Kim TI, Lee YK, Park SG, Choi IS, Ban JO, Park HK, Nam SY, Yun YW, Han SB, Oh KW, Hong JT (2009) L-Theanine, an amino acid in green tea, attenuates beta-amyloid-induced cognitive dysfunction and neurotoxicity: Reduction in oxidative damage and inactivation of ERK/p38 kinase and NF-kappaB pathways. Free Radic Biol Med 47, 1601-1610.
12. Lee JW, Lee YK, Lee BJ, Nam SY, Lee SI, Kim YH, Kim KH, Oh KY, Hong JT (2010) Inhibitory effect of ethanol extract of Magnolia officinalis and 4-O-methylhonokiol on memory impairment and neuronal toxicity induced by beta-amyloid. Pharmacol Biochem Behv 95, 31-40.
13. Lee YK, Yuk DY, Lee JW, Lee SY, Ha TY, Oh KW, Yun YP, Hong JT (2009) (-)-Epigallocatechin-3-gallate prevents lipopolysaccharide-induced elevation of beta-amyloid generation and memory deficiency. Brain Res 1250, 164-174.
14. Cerpa W, Dinamrca MC, Inestrosa NC (2008) Structurefunction implications in Alzheimer's disease: effect of Abeta oligomers at central synapses. Curr Alzheimer Res 5, 233-243. (Pubitemid 351840275)
15. Bajpai VK,Yoon JI, Kang SC (2009) Antioxidant and antidermatophytic activities of essential oil and extracts of Magnolia liliflora Desr. Food Chem Toxicol 47, 2606-2612.
16. Lee JW, Lee YK, Ban JO, Ha TY, Yun YP, Han SB, Oh KW, Hong JT (2009) Green tea (-)-epigallocatechin-3-gallate inhibits beta-amyloid-induced cognitive dysfunction through modification of secretase activity via inhibition of ERK and NF-kappaB pathways in mice. J Nutr 139, 1987-1993.
17. Lee YK, Choi IS, Ban JO, Lee HJ, Lee US, Han SB, Jung JK, OhKW, Hong JT (2011) 4-O-methylhonokiol attenuatedamyloid-induced memory impairment through reduction of oxidative damages via inactivation of p38 kinase. J Nutr Biochem 22, 476-486.
18. Zhou HY, Shin EM, Guo LY, Youn UJ, Bae K, Kang SS, Zou LB, Kim YS (2008) Anti-inflammatory activity of 4-methoxyhonokiol is a function of the inhibition of iNOS and COX-2 expression in RAW 264.7 macrophages via NFkappaB, JNK and p38 MAPK inactivation. Eur J Pharmacol 586, 340-349.
19. Fujita S, Taira J (2000) Biphenyl compounds are hydroxyl radical scavengers: their effective inhibition for UV-induced mutation in Salmonella typhimurium TA102. Free Radic Biol Med 17, 273-277.
20. Harris-White ME, Frautschy SA (2005) Low density lipoprotein receptor-related proteins (LRPs), Alzheimer's and cognition. Curr Drug Targets CNS Neurol Disord 4, 469-480. (Pubitemid 41448375)
21. Lane RM, Farlow MR (2005) Lipid homeoatasis and apolipoprotein E in the development and progression of Alzheimer's disease. J Lipid Res 46, 949-968.
22. Dorfman VB, Pasquini L, Riudavets M, Ĺopez-Costa JJ, Villegas A, Troncoso JC, Lopera F, Castaño EM, Morelli L (2010) Differential cerebral deposition of IDE and NEP in sporadic and familial Alzheimer's disease. Neurobiol Aging 10, 1743-1757.
23. Leal MC, Dorfman VB, Gamba AF, Frangione B,Wisniewski T, Castaño EM, Sigurdsson EM, Morelli L (2006) Plaqueassociated overexpression of insulin-degrading enzyme in the cerebral cortex of aged transgenic tg2576 mice with Alzheimer pathology. J Neuropathol Exp Neurol 65, 976-987. (Pubitemid 44521798)
24. Wang R, Wang S, Malter JS, Wang DS (2009) Effects of 4-hydroxy-nonenal and Amyloid-beta on expression and activity of endothelin converting enzyme and insulin degrading enzyme in SH-SY5Y cells. J Alzheimers Dis 17, 489-501.
25. Wang R, Malter JS, Wang DS (2010) N-acetylcysteine prevents 4-hydroxynonenal-and amyloid-beta-induced modification and inactivation of neprilysin in SH-SY5Y cells. J Alzheimers Dis 19, 179-189.
26. Watanabe K,Watanabe H, Goto Y, Yamaguchi M, Yamamoto N, Hagino K (1983) Pharmacological properties of magnolol and honokiol extracted from Magnolia officinalis: central depressant effects. Planta Med 49, 103-108. (Pubitemid 14239052)
27. Kuribara H, Stavinoha WB,Maruyama Y (1998) Behavioural pharmacological characteristics of honokiol, an anxiolytic agent present in extracts of Magnolia bark, evaluated by an elevated plus-maze test in mice. J Pharm Pharmacol 50, 819-826. (Pubitemid 28379279)
28. Lin YR, Chen HH, Ko CH, Chan MH (2007) Effects of honokiol and magnolol on acute and inflammatory pain models in mice. Life Sci 81, 1071-1078.
29. Munroe ME, Arbiser JL, BishopGA(2007) Honokiol, a natural plant product, inhibits inflammatory signals and alleviates inflammatory arthritis. J Immunol 179, 753-763.
30. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 100, 4162-4167. (Pubitemid 36418174)
31. Chen CL, Chang PL, Lee SS, Peng FC, Kuo CH, Chang HT (2007) Analysis of magnolol and honokiol in biological fluids by capillary zone electrophoresis. J Chromatogr A 1142, 240-244.
32. Dikalov S, Losik T, Arbiser JL (2008) Honokiol is a potent scavenger of superoxide and peroxyl radicals. Biochem Pharmacol 76, 589-596.
33. Oh JH, Kang LL, Ban JO, Kim YH, Kim KH, Han SB, Hong JT (2009) Anti-inflammatory effect of 4-O-methylhonokiol, a novel compound isolated from Magnolia officinalis through inhibition of NF-kappaB. Chem Biol Interact 180, 506-514.
34. Lee YK, Yuk DY, Kim TI, Kim YH, Kim KT, Kim KH, Lee BJ, Nam SY, Hong JT (2009) Protective effect of the ethanol extract of Magnolia officinalis and 4-O-methylhonokiol on scopolamine-induced memory impairment and the inhibition of acetylcholinesterase activity. Nat Med (Tokyo) 63, 274-282.
35. Hwang DY, Cho JS, Lee SH, Chae KR, Lim HJ, Min SH, Seo SJ, Song YS, Song CW, Paik SG, Sheen YY, Kim YK (2004) Aberrant expressions of pathogenic phenotype in Alzheimer's disease transgenic mice carrying NSE-controlled APPsw. Exp Neurol 186, 20-32. (Pubitemid 38229902)
36. Hwang DY, Chae KR, Kang TS, Hwang JH, Lim CH, Kang HK, Goo JS, Lee MR, Lim HJ, Min SH, Cho JY, Hong JT, Song CW, Paik SG, Cho JS, Kim YK (2002) Alterations in behavior, amyloid beta-42, caspase-3, and Cox-2 in mutant PS2 transgenic mouse model of Alzheimer's disease. FASEB J 16, 805-813. (Pubitemid 34615129)
37. Fezoui Y, Teplow DB (2002) Kinetic studies of amyloid beta-protein fibril assembly. Differential effects of alpha-helix stabilization. J Biol Chem 277, 36948-36954.
38. Finkel T, Holbrook NJ (2000) Oxidants, oxidative stress and the biology of ageing. Nature 408, 239-247.
39. Gibson GE, Zhang H (2000) Abnormalities in oxidative processes in non-neuronal tissues from patients with Alzheimer's disease. J Alzheimers Dis 3, 329-338.
40. HarkanyT, Abrah́amI,Ḱonya C, Nyakas C, Zaŕandi M, Penke B, Luiten PG (2000) Mechanisms of beta-amyloid neurotoxicity: perspectives of pharmacotherapy. Rev Neurosci 11, 329-382.
41. Sudoh S, Frosch MP, Wolf BA (2002) Differential effects of proteases involved in intracellular degradation of amyloid beta-protein between detergent-soluble and-insoluble pools in CHO-695 cells. Biochemistry 41, 1091-1099. (Pubitemid 34083761)
42. Lee SY, Hwang DY, Kim YK, Lee JW, Shin IC, Oh KW, Lee MK, Lim JS, Yun DY, Hong JT (2006) PS2 mutation increases neuronal cell vulnerability to neurotoxicants through activation of caspase-3 by enhancing of ryanodine receptor-mediated calcium release. FASEB J 20, 151-153. (Pubitemid 43100497)
43. Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon M, Tan H, Games D, Lieberburg I, Schenk D, Seuber P, McConlogue L (1997) Amyloid precursor protein processing andAbeta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci USA 94, 1550-1555.
44. Calhoun ME, Wiederhold KH, Abramowski D, Phinney AL, Probst A, Sturchler-Pierrat C, Staufenbiel M, Sommer B, JuckerM(1998) Neuron loss in APP transgenic mice. Nature 395, 755-756. (Pubitemid 28485431)
45. Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT (2000) APPSW transgenic mice develop age-related A bata deposits and neuropil abnormalities, bur no neuronal loss in CA1. J Neuropathol Exp Neurol 56, 965-973. (Pubitemid 27386126)
46. Tamagno E, Guglielmotto M, Aragno M, Borghi R, Autelli R, Giliberto L, Muraca G, Danni O, Zhu X, Smith MA, Perry G, Jo DG, Mattson MP, Tabaton M (2008) Oxidative stress activates a positive feedback between the gamma-and beta secretase cleavages of the beta-amyloid precursor protein. J Neurochem 104, 683-695.
47. Selznick LA, Holtzman DM, Han BH, G̈okden M, Srinivasan AN, Jr., Johnson EM, Roth KA (1999) In situ immunodetection of neuronal caspase-3 activation in Alzheimer disease. J Neuropathol Exp Neurol 58, 1020-1026. (Pubitemid 29441930)
48. Hernandez F, Gomez de Barreda E, Fuster-Matanzo A, Lucas JJ,Avila J (2010) GSK3: a possible link between beta amyloid peptide and tau protein. Exp Neurol 223, 322-325.
49. Hu S, Begum AN, Jones MR, Oh MS, Beech WK, Beech BH, Yang F, Chen P, Ubeda OJ, Kim PC, Davies P, Ma Q, Cole GM, Frautschy SA (2009) GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals. Neurobiol Dis 33, 193-206.
50. Puri R, Suzuki T, Yamakawa K, Ganesh S (2009) Hyperphosphorylation and aggregation of tau in laforin-deficient mice, an animal model for lafora disease. J Biol Chem 284, 22657-22663.
51. Stein TD, Johnson JA (2002) Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J Neurosci 22, 7380-7388. (Pubitemid 35386337)
52. Lee YJ, Choi IS, Park MH, Lee YM, Song JK, Kim YH, Kim KH, Hwang DY, Jeong JH, Yun YP, Oh KW, Jung JK, Han SB, Hong JT (2010) 4-O-methylhonokiol attenuates memory impairment in presenilin 2 mutant mice through reduction of oxidative damage and inactivation of astrocytes and the ERK pathway. Free Radic Biol Med 50, 66-77.
53. Tsai TH, Chou CJ, Chen CF (1996) Pharmacokinetics and brain distribution of magnolol in the rat after intravenous bolus injection. J Pharm Pharmacol 48, 57-59. (Pubitemid 26128686)
54. Lin YL, Chen HH, Ko CH, Chan MH (2005) Differential inhibitory effect of honokiol and magnolol on excitatory amino acid-evoked cation signals and NMDA-induced seizures. J Neuropharm 542, 550-558.
55. Chiu JH, Ho CT,Wei YH, Lui WY, Hong CY (2007) In vitro and in vivo protective effect of honokiol on rat liver from peroxidative injury. Life Sci 61, 1961-1971.
56. Seo JJ, Lee SH, Lee YS, Kwon BM, Ma Y, Hwang BY, Hong JT, Oh KW (2007) Anxiolytic-like effects of obovatol isolated from Magnolia obovata: involvement of GABA/benzodiazepine receptors complex. Prog Neuropsychopharmacol Biol Psychiatry 31, 1363-1369. (Pubitemid 47302547)